Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
31 results:

  • 1. Allosteric shp2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.
    Han X; Wang W; Wang R; Zhang W; Zhu L; Xu Q; Guo W; Gu Y
    Biochem Biophys Res Commun; 2024 May; 709():149812. PubMed ID: 38564942
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
    Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
    Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. shp2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
    Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
    Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. MUC1-C is necessary for shp2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
    Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
    Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Efficacious Combination Drug treatment for colorectal cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. shp2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis.
    Li Y; Zhou H; Liu P; Lv D; Shi Y; Tang B; Xu J; Zhong T; Xu W; Zhang J; Zhou J; Ying K; Zhao Y; Sun Y; Jiang Z; Cheng H; Zhang X; Ke Y
    J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36626230
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 colorectal cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeting RAS Mutant colorectal cancer with Dual Inhibition of MEK and CDK4/6.
    Sorokin AV; Kanikarla Marie P; Bitner L; Syed M; Woods M; Manyam G; Kwong LN; Johnson B; Morris VK; Jones P; Menter DG; Lee MS; Kopetz S
    Cancer Res; 2022 Sep; 82(18):3335-3344. PubMed ID: 35913398
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Predictive and Therapeutic Implications of a Novel PLCγ1/shp2-Driven Mechanism of Cetuximab Resistance in Metastatic colorectal cancer.
    Cruz-Duarte R; Rebelo de Almeida C; Negrão M; Fernandes A; Borralho P; Sobral D; Gallego-Paez LM; Machado D; Gramaça J; Vílchez J; Xavier AT; Ferreira MG; Miranda AR; Mansinho H; Brito MJ; Pacheco TR; Abreu C; Lucia-Costa A; Mansinho A; Fior R; Costa L; Martins M
    Clin Cancer Res; 2022 Mar; 28(6):1203-1216. PubMed ID: 34980600
    [TBL] [Abstract] [Full Text] [Related]  

  • 11.
    Coupez D; Hulo P; Touchefeu Y; Denis MG; Bennouna J
    Expert Opin Biol Ther; 2021 Oct; 21(10):1325-1334. PubMed ID: 34378483
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. shp2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon cancer.
    Wei B; Xu L; Guo W; Wang Y; Wu J; Li X; Cai X; Hu J; Wang M; Xu Q; Liu W; Gu Y
    Cancer Res; 2021 Jun; 81(12):3215-3228. PubMed ID: 33820798
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation.
    Buday L; Vas V
    Cancer Metastasis Rev; 2020 Dec; 39(4):1067-1073. PubMed ID: 32936431
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. PCC0208023, a potent shp2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
    Toomey S; Carr A; Mezynski MJ; Elamin Y; Rafee S; Cremona M; Morgan C; Madden S; Abdul-Jalil KI; Gately K; Farrelly A; Kay EW; Kennedy S; O'Byrne K; Grogan L; Breathnach O; Morris PG; Eustace AJ; Fay J; Cummins R; O'Grady A; Kalachand R; O'Donovan N; Kelleher F; O'Reilly A; Doherty M; Crown J; Hennessy BT
    J Transl Med; 2020 Feb; 18(1):99. PubMed ID: 32087721
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
    Costigan DC; Dong F
    Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. shp2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
    Ahmed TA; Adamopoulos C; Karoulia Z; Wu X; Sachidanandam R; Aaronson SA; Poulikakos PI
    Cell Rep; 2019 Jan; 26(1):65-78.e5. PubMed ID: 30605687
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in colorectal cancer Cells.
    Ressa A; Bosdriesz E; de Ligt J; Mainardi S; Maddalo G; Prahallad A; Jager M; de la Fonteijne L; Fitzpatrick M; Groten S; Altelaar AFM; Bernards R; Cuppen E; Wessels L; Heck AJR
    Mol Cell Proteomics; 2018 Oct; 17(10):1892-1908. PubMed ID: 29970458
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A Deregulated PI3K-AKT Signaling Pathway in Patients with colorectal cancer.
    Zhang T; Ma Y; Fang J; Liu C; Chen L
    J Gastrointest Cancer; 2019 Mar; 50(1):35-41. PubMed ID: 29110225
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma.
    Jiang C; Long J; Liu B; Xu M; Wang W; Xie X; Wang X; Kuang M
    J Exp Clin Cancer Res; 2017 Jul; 36(1):99. PubMed ID: 28750679
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.